Efficacité du baricitinib et du tofacitinib par rapport aux bDMARDs dans la PR : résultats d'une étude de cohorte utilisant les données d'un registre national suédois

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068

Data from the Swedish Rheumatology Quality Register and Swedish Registries, show a higher treatment retention and overall equivalent or better treatment response on baricitinib, compared with bDMARDs or tofacitinib, but no statistically significant differences between tofacitinib and bDMARDs.In this largest population-based study to date, comparing RA patients initiating baricitinib, tofacitinib or bDMARDs, Barbulescu, et al. help to fill some of the current knowledge gaps surrounding the efficacy of JAKinibs compared to bDMARDs.

LinkedIn